Captopril-13C5,15N

Captopril-13C5,15N (SQ 14225-13C5,15N) is 13C and 15N labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM[1][2][3].

SQ 14225-13C5,15N

12352211

Angiotensin-converting Enzyme (ACE) ; Isotope-Labeled Compounds

Metabolic Enzyme/Protease; Others

Cancer-programmed cell death

Cardiovascular Disease; Cancer

O=C([C@@H](CS)C)[15N]1[13CH2][13CH2][13CH2][13C@H]1[13C](O)=O

C4 13C5H15 15NO3S

223.24

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Afrin S, et al. Eritadenine from Edible Mushrooms Inhibits Activity of Angiotensin Converting Enzyme in Vitro. J Agric Food Chem. 2016;64 (11) :2263-2268.|[3]Esmaeili S, et al. Captopril/enalapril inhibit promiscuous esterase activity of carbonic anhydrase at micromolar concentrations: An in vitro study. Chem Biol Interact. 2017;265:24-35.|[4]Li N, et al. Simplified captopril analogues as NDM-1 inhibitors. Bioorg Med Chem Lett. 2014;24 (1) :386-389.|[5]Tzakos, A.G., et al., The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme. Bioorg Med Chem Lett, 2006. 16 (19) : p. 5084-7.|[6]Song, J.C. and C.M. White, Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet, 2002. 41 (3) : p. 207-24.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-B0368S1/

Isotope-Labeled Compounds

No Development Reported